Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 3 mg EV Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women.
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2014
At a glance
- Drugs Estradiol valerate/levomefolic acid (Primary) ; Estradiol valerate; Levomefolic acid
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Bayer
- 13 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Dec 2009 New trial record